# Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

> **NCT04313153** · PHASE3 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 319 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Vadadustat
- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT04313153
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-27
- **Primary completion:** 2021-11-26
- **Final completion:** 2022-06-22
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04313153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04313153, "Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04313153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*